Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this initiative is to stimulate basic research, discovery, and early translational research to enable and accelerate the generation of highly efficacious pre-erythrocytic stage malaria vaccines, including sporozoite-based vaccines    . Cross-fertilization and collaboration among investigators from malaria vaccine research and other basic research areas such as parasite biology, parasite genomics, pathogenesis, and host immunology are highly encouraged. The goal is to generate one or more promising vaccine candidates against human malaria that exhibit performance superior to currently available sporozoite-based vaccines and are suitable for further downstream process development and future clinical evaluation.


  • Letter of Intent Due Date(s): December 17, 2019
  • Application Due Date(s): January 17, 2020​

RFA-AI-19-059 Expiration Date January 18, 2020

Agency Website



Amount Description

The application budget may not exceed $750K in direct costs per year and should reflect the actual needs of the project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.


      Funding Type





      Medical - Basic Science
      Medical - Clinical Science
      Medical - Translational

      External Deadline

      January 17, 2020